BridgeBio CEO Neil Kumar at BIO22 (J.T. MacMillan Photography for Endpoints News)

Bridge­Bio's make-or-break read­out is slat­ed for Mon­day, as CEO posts a cryp­tic mes­sage about Odysseus

Bridge­Bio said it would share da­ta on a crit­i­cal Phase III tri­al on Mon­day morn­ing, in what’s ex­pect­ed to be a make-or-break mo­ment for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.